Apollomics Inc. FOSTER CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) — Apollomics Incl. (Nasdaq: APLM) (“Apollomics” or the “Company”), an advanced clinical-stage biopharmaceutical company developing multiple oncology drug candidates to treat difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2024 ended June 30, 2024, and highlighted updates to its pipeline. […]